Clinical Trials
15 trialsNCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
NCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT06100796 2023-10-25
NSCLC
Assiut University
Unknown
NCT05418660 2023-09-18
I-STOP
University of Milano Bicocca
Unknown
NCT04107168 2023-02-16
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT04359199 2023-02-10
QUASAR
University of California, San Diego
Unknown
NCT05578170 2023-02-03
PROBES
Nanfang Hospital, Southern Medical University
Unknown
NCT04740996 2022-02-07
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
ChineseAMS
Unknown
NCT04465942 2021-08-23
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Unknown
NCT04860076 2021-04-26
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
Asylia Diagnostics BV
Unknown
NCT03373955 2021-03-18
A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients
Sichuan University
Unknown
NCT04771715 2021-02-25
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
Unknown
NCT04683445 2020-12-24
Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT04115410 2020-05-28
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
Unknown
NCT04306042 2020-03-12
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Guangdong Association of Clinical Trials
Unknown